Alaunos Therapeutics, Inc. Net Income Loss

• Alaunos Therapeutics, Inc. showed an increase of +10.8% in Net Income Loss from 2024 to 2025.
• This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 19 years of available data (2007 to 2025), Alaunos Therapeutics, Inc.'s Net Income Loss has grown by 84.3%.
• Historical annual values: Fiscal year 2025: -$4.18 million | Fiscal year 2024: -$4.68 million | Fiscal year 2023: -$4.68 million | Fiscal year 2022: -$37.73 million | Fiscal year 2021: -$78.75 million | Fiscal year 2020: -$79.98 million | Fiscal year 2019: -$117.80 million | Fiscal year 2018: -$53.12 million | Fiscal year 2017: -$54.32 million | Fiscal year 2016: -$165.30 million | Fiscal year 2015: -$120.09 million | Fiscal year 2014: -$31.78 million | Fiscal year 2013: -$57.11 million | Fiscal year 2012: -$96.13 million | Fiscal year 2011: -$63.78 million | Fiscal year 2010: -$32.67 million | Fiscal year 2009: -$7.65 million | Fiscal year 2008: -$25.23 million | Fiscal year 2007: -$26.61 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026